KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Other Non-Current Assets (2018 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Other Non-Current Assets for 7 consecutive years, with $93000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Non-Current Assets fell 89.29% year-over-year to $93000.0, compared with a TTM value of $93000.0 through Sep 2025, down 89.29%, and an annual FY2024 reading of $823000.0, down 45.75% over the prior year.
  • Other Non-Current Assets was $93000.0 for Q3 2025 at Aurinia Pharmaceuticals, roughly flat from $93000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $13.4 million in Q1 2023 and bottomed at $93000.0 in Q2 2025.
  • Average Other Non-Current Assets over 5 years is $5.1 million, with a median of $1.5 million recorded in 2023.
  • The sharpest move saw Other Non-Current Assets tumbled 94.09% in 2022, then soared 1384.11% in 2023.
  • Year by year, Other Non-Current Assets stood at $11.8 million in 2021, then increased by 12.68% to $13.3 million in 2022, then crashed by 88.63% to $1.5 million in 2023, then tumbled by 45.75% to $823000.0 in 2024, then plummeted by 88.7% to $93000.0 in 2025.
  • Business Quant data shows Other Non-Current Assets for AUPH at $93000.0 in Q3 2025, $93000.0 in Q2 2025, and $823000.0 in Q1 2025.